![GSK spin-off to create consumer healthcare giant](https://www.berlinertageblatt.de/media/shared/articles/9d/4f/e5/GSK-spin-off-to-create-consumer-hea-959372.jpg)
-
Trump offers tech sector policy flips ahead of election
-
Spacecraft to swing by Earth, Moon on path to Jupiter
-
What's the fallout of Mexican drug lords' capture?
-
Video game makers see actors as AI 'data,' says union on strike
-
Chinese qualifier Shang to face Thompson in ATP Atlanta semis
-
Concern grows as Venezuela blocks election observers
-
'Massive attack' on French rail threatens more chaos
-
'We did it!': France breathes sigh of relief after Olympics ceremony
-
Blinken, in Laos, set for talks with Chinese foreign minister
-
Regional concern grows as Venezuela blocks vote observers
-
Historic river parade, Dion show-stopper ignite Paris Olympics
-
Rainy Paris Olympic parade dampens many spectators' spirits
-
G20 pledges to work together to tax ultra-rich
-
The one of a kind Paris opening ceremony: five memorable moments
-
Justin Timberlake seeks to dismiss DUI case
-
Warner Brothers Discovery sues NBA over Amazon rights deal
-
Kobe Bryant locker, Maradona jersey up for auction in New York
-
Historic river parade launches Paris Olympics
-
Stocks rise as US inflation data boosts rate cut hopes
-
New York family of Holocaust victim reclaims Nazi-looted art
-
NASA Mars rover captures rock that could hold fossilized microbes
-
Thousands evacuate season's biggest wildfire in northern California
-
Sinaloa Cartel co-founder pleads not guilty after stunning US capture
-
Ethiopia mourns victims of landslide tragedy
-
Lady Gaga adds sparkle to star-studded Olympic show
-
Airbus and Boeing supremacy secure despite turbulence
-
Teams sail down Seine in rain-soaked Olympics opening ceremony
-
Norris hoping for more after topping Belgian practice times
-
West Indies' treble strike rocks England in third Test
-
Trump slams rivals as he meets Netanyahu in Florida
-
Olympic opening ceremony under way on River Seine
-
Mott's England future uncertain as ECB chief fails to offer support
-
Trump meets Israeli PM Netanyahu in Florida
-
S.African police say 95 Libyans detained at suspected military camp
-
Blinken set for talks with Chinese counterpart in Laos
-
Norris heads Piastri in McLaren one-two at Belgian GP practice
-
G20 seeks common ground on taxing super-rich
-
European medicines watchdog rejects new Alzheimer's drug
-
Harris gets vital Obama backing in battle against Trump
-
Habib, Ebden eye Alcaraz and Djokovic shocks at Olympics tennis
-
Stocks rise as inflation data boosts rate cut hopes
-
Long queues, ticketing problems ahead of Paris opening ceremony
-
Two Sinaloa Cartel leaders face US charges after stunning capture
-
Spain train driver jailed for 2.5 years over deadly 2013 crash
-
Paris poised for Olympic opening ceremony spectacular
-
Judoka fails doping test in first case at Paris Olympics
-
Holder and Da Silva keep England at bay after West Indies collapse
-
Alpine F1 boss Bruno Famin to leave in August
-
Ethiopia declares three days of mourning after landslide tragedy
-
Brazilian dunes dotted with dazzling pools make UNESCO heritage list
![GSK spin-off to create consumer healthcare giant](https://www.berlinertageblatt.de/media/shared/articles/9d/4f/e5/GSK-spin-off-to-create-consumer-hea-959372.jpg)
GSK spin-off to create consumer healthcare giant
British drugs giant GlaxoSmithKline on Monday demerges its newly-named consumer healthcare unit Haleon, resulting in what is set to be London's largest new stock market listing in more than a decade.
The new company -- owning brands including Sensodyne toothpaste, pain relief drug Panadol and cold treatment Theraflu -- is set for a valuation of about £40 billion ($47.4 billion) when it begins trading on the London stock market, according to Bloomberg.
The major strategy shift by GSK chief executive Emma Walmsley comes after she has faced intense activist shareholder pressure over the company's delays in producing Covid jabs and treatments.
- 'Landmark London listing -
"This will be the largest London stock market listing in a decade, with the new company becoming a big beast with a new skin in the consumer goods world," said Susannah Streeter, senior investment and markets analyst at Hargreaves Lansdown.
It is set to be the capital's biggest listing since Swiss mining giant Glencore was valued at £38 billion on entry in 2011.
GSK, which owns 68 percent of Haleon, plans to retain six percent of the group following the spin-off.
US pharmaceutical titan Pfizer has said it plans to sell its 32-percent minority stake.
Walmsley, who had led the consumer unit prior to her promotion as head of GSK in 2017, has described the demerger as the group's most significant corporate change in 20 years.
The split sees GSK "parcelling off a considerable quantity of its sizeable debt pile into Haleon, expected to be around £10 billion", Streeter said.
Haleon could join London's top-tier FTSE 100 depending on its market valuation.
Walmsley, part of a group of less than 10 women chief executives running companies on the benchmark index, sees more long-term value in the demerger than a sale.
GSK at the start of the year rejected a £50 billion bid for the unit from consumer goods titan Unilever.
- Vaccine push -
Alongside the demerger, GSK is expanding further into the field of vaccines, having in May snapped up US biopharmaceutical firm Affinivax for up to $3.3 billion.
Also this year, the British company spent $1.9 billion on US group Sierra Oncology, a specialist in medicines for rare forms of cancer.
Keith Bowman, analyst at Interactive Investor, said the demerger was aimed at giving GSK "increased management focus to each respective business".
This was the case "particularly for its pharma business which has underperformed rivals such as (Covid vaccine-maker) AstraZeneca over recent years", he told AFP.
GSK is set to receive £7 billion in dividends at separation.
The consumer healthcare division, whose portfolio of products includes also Centrum multivitamins and anti-inflammatory Voltaren, generates annual sales of about £10 billion.
Haleon will be headquartered in Weybridge, southwest of London.
"The idea is that a more focused consumer business will help boost sales," said Streeter.
"There will be no change at the top... which is a vote of confidence in Brian McNamara, a former Procter & Gamble executive who has led the division for eight years."
J.Fankhauser--BTB